There is no Northern Ireland equivalent to NICE, SMC or AWMSG . In practice, most NICE decisions are implemented locally, meaning that a positive NICE decision should lead to reimbursement in Northern Ireland. Though this should not affect a brand’s overarching UK launch and communications strategy, it is important to know the local stakeholder bodies that operate in Northern Ireland and how they engage with NICE and the NHS.
Northern Ireland’s Payer Stakeholders
In Northern Ireland, the national health service is known as Health and Social Care (HSC). It provides health services and medicines free of charge to residents. These services are delivered by five HSC trusts, distributed by region: Belfast, South Eastern, Southern, Northern and Western.
Since 2006 the Department of Health, Social Services and Public Safety (HPSS), a part of HSC, reached a formal arrangement in which it reviews NICE decisions to determine whether they are locally applicable. Any required amendments are made and the decision then ratified and reflected by local HSC trusts. The policy methodology, however, states that it is not a reassessment of NICE evidence but rather a proofing.
Important Points to Keep in Mind
There is no separate Health Technology Appraisal (HTA) body in Northern Ireland that assesses medicines for use within the HSC. Northern Ireland essentially adopts NICE guidance after confirming it is applicable locally, despite NICE not formally considering Northern Ireland when developing its guidance.
Implications for Industry
For the purposes of reimbursement, you may consider Northern Ireland to be similar to a region of England in that it will in the main adopt NICE guidance and has no set, national methodology for conducting HTA in the absence of NICE guidance. However, awareness of the local context and identification of stakeholders that apply NICE guidance across the UK will help ensure smoother product launch and uptake.
The GLOBALHealthPR team has years of experience in Northern Ireland, all the other countries of the UK, and other EU markets and can offer valuable insights to your marketing and market access teams.
for a complimentary 30-minute consultation
The Latest From Our Blog
February 28th is World Rare Disease Day, but why is that important? Check out our infographic to learn more about rare diseases, and how they can have a big impact on the healthcare landscape.
Dilemmas Over the Approval and Delivery of New Health Technologies in a Fragmented and Inefficient System
There is no doubt that advances in health technology have provided tremendous benefits to patients. In Argentina, patients have pursued access to innovative treatments through court actions, which have been increasing in frequency along with each new drug approval and diagnosis method.
The ACIAPO Foundation of Argentina, together with other patient associations in the region, inquired into the major difficulties encountered by affected people after they receive their diagnoses. The most frequent ones: bureaucracy and exceedingly long waiting times. GLOBALHealthPR Argentina partner Paradigma explains.
The Pharmaceutical Benefits Scheme, or PBS, is a programme administered by the Australian Government to provide patients with heavily subsidised access to a broad range of prescription medicines. Despite its expansion over the years, access to treatments for some rare disorders under the PBS remains elusive today.
Whether we’re talking about a family, business or country, significant growth inevitably causes a ripple effect of change and requires careful management to keep the proverbial engines running smoothly. As we’ve seen with Google and Apple, properly managed growth can...
When does your employer pay you for your toil? For the Brits reading this post it is likely to be the 25th of each month; I’ve been paid on this day since my first post-graduation job as a research microbiologist in 1995. Non-UK resident readers will have a different...